US Malignant Pleural Mesothelioma Treatment Market Insights: Immunotherapy Advances from Merck & Co., Bristol-Myers Squibb, and Eli Lilly Boost Market Growth

The U.S. Malignant Pleural Mesothelioma (MPM) Treatment Market is estimated at US$ 0.14 billion in 2024, with growth projected at a CAGR of 6.4% during 2025-2034. The market is expanding steadily as diagnosis rates improve and demand rises for more effective therapies targeting this aggressive and rare cancer.

The U.S. maintains a strong position in the global MPM treatment landscape, supported by advanced oncology infrastructure, expanding use of immunotherapies, and active clinical development of novel drug combinations. Growing investment in precision medicine, improved biomarker-based treatment approaches, and a robust pharmaceutical pipeline continue to reinforce the market's long-term growth outlook.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/malignant-pleural-mesothelioma-treatment-market?sai-v

The MPM Treatment Market focuses on therapies, drugs, and multimodal approaches aimed at managing and improving outcomes for patients with malignant pleural mesothelioma, a rare and aggressive cancer caused primarily by asbestos exposure.

Key Developments

United States

✅ October 2025: The FDA granted Fast Track designation to a new investigational therapy for unresectable malignant pleural mesothelioma, accelerating its clinical pathway and supporting faster access to advanced treatment options.

✅ September 2025: A major U.S. clinical research center reported promising results from perioperative immunotherapy using nivolumab alone or in combination with ipilimumab, demonstrating improved safety and feasibility for operable MPM patients.

✅ January 2025: A biotechnology company developing mesothelin-targeted therapies announced positive Phase 1 outcomes for its new candidate, showing early signs of clinical activity and strengthening the future treatment pipeline for MPM.

Japan

✅ September 2025: Post-marketing surveillance data confirmed the continued safety and consistent efficacy of nivolumab in Japanese MPM patients previously treated with chemotherapy, reinforcing its role in second-line therapy.

✅ July 2025: Japanese oncology centers reported increasing use of immune-checkpoint inhibitors in combination regimens for advanced MPM, supported by national clinical practice guidelines and real-world treatment outcomes.

Mergers & Acquisitions

✅ June 2025 (United States): A leading oncology-focused pharmaceutical company entered a strategic collaboration with a biotech developing mesothelin-directed immunotherapies, aiming to jointly advance next-generation MPM treatment candidates.

✅ April 2025 (Japan): A major Japanese pharmaceutical firm formed a development partnership with a U.S.-based biotech to co-develop immunotherapy combinations for refractory mesothelioma, expanding access to novel treatment mechanisms.

Key Players:

Eli Lilly and Company | Bristol-Myers Squibb Company | Accord Healthcare US | Merck & Co., Inc. | Novartis AG | Pfizer Inc. | MEDYRA Pharmaceutical | Teva Pharmaceuticals USA, Inc. | Hikma Pharmaceuticals PLC | AstraZeneca

Key Highlights :

• Eli Lilly and Company - Reported USD 34.1 billion in 2024 revenue, driven by strong growth in oncology, diabetes, and immunology therapeutics, reinforcing its leadership in advanced pharmaceutical innovation.

• Bristol-Myers Squibb Company - Achieved USD 45.0 billion in 2024 revenue, supported by continued demand for its immuno-oncology and cardiovascular drug portfolio across global markets.

• Accord Healthcare US - A key generics and biosimilars manufacturer with strong nationwide distribution and continuous portfolio expansion, contributing significantly to the U.S. affordable medicines segment.

• Merck & Co., Inc. - Delivered USD 63.1 billion in 2024 revenue, led by strong performance in oncology, vaccines, and hospital acute care therapeutics.

• Novartis AG - Recorded USD 46.5 billion in 2024 revenue, driven by specialty medicines, gene-targeted therapies, and high-growth immunology and oncology segments.

• Pfizer Inc. - Generated USD 58.5 billion in 2024 revenue, maintaining a strong presence in vaccines, oncology, internal medicine, and innovative therapeutic platforms.

• MEDYRA Pharmaceutical - Strengthened its position in specialty pharmaceuticals and niche therapeutic areas, supported by expanding product launches and growing regional market penetration.

• Teva Pharmaceuticals USA, Inc. - A major player in the U.S. generics market with a broad therapeutic portfolio and strong presence across chronic disease treatments and specialty care.

• Hikma Pharmaceuticals PLC - Reported USD 2.5 billion in revenue, backed by strong performance in generics, injectable medicines, and branded pharmaceutical segments.

• AstraZeneca - Achieved USD 45.8 billion in 2024 revenue, driven by sustained growth in oncology, cardiovascular, renal, and respiratory therapeutics.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=malignant-pleural-mesothelioma-treatment-market?sai-v

Market Drivers & Growth

- Increasing global incidence of asbestos exposure-particularly in construction, shipbuilding, and industrial sectors-is a key driver of demand for MPM treatment solutions.

- Rising adoption of multimodal therapies including surgery, chemotherapy, and radiation is supporting market growth.

- Growing uptake of immunotherapies such as immune checkpoint inhibitors is expanding treatment options and improving survival outcomes.

- Advancements in diagnostic imaging, biopsy procedures, and biomarker-based detection are enabling earlier diagnosis and more effective treatment planning.

- Increasing clinical trials exploring novel therapies-gene therapy, tumor-treating fields (TTF), and targeted therapy-are fueling innovation in the treatment landscape.

- Expansion of healthcare infrastructure and supportive reimbursement policies in developed regions are enhancing patient access to advanced treatments.

Industrial Advances & Developments

- Introduction of PD-1/PD-L1 inhibitors and other immunotherapies as frontline or second-line treatment for improved patient response rates.

- Ongoing development of novel targeted therapies aimed at mesothelioma-specific genetic alterations such as BAP1 mutations.

- Advancements in minimally invasive surgical techniques for cytoreductive surgery and pleurectomy/decortication to improve patient recovery.

- Increasing use of Tumor Treating Fields (TTF) technology as a non-invasive adjunct therapy showing promising survival benefits.

- Growth in combination therapy trials integrating immunotherapy, chemotherapy, and radiation for synergistic treatment outcomes.

- Development of liquid biopsy technologies and next-gen sequencing to improve accuracy in early MPM detection and therapy selection.

Regional Insights

North America

Dominant market driven by high diagnosis rates, strong presence of specialized cancer treatment centers, active clinical trials, and early adoption of advanced therapies including immunotherapy.

Europe

Strong growth supported by ongoing asbestos exposure cases, robust healthcare systems, increasing use of novel targeted drugs, and rising government support for rare cancer research.

Asia-Pacific

Fastest-growing region due to expanding industrial sectors, rising asbestos-related disease burden, improving cancer care infrastructure, and increasing participation in global clinical trials.

Latin America

Growing adoption driven by increasing awareness of asbestos risks, improving oncology care, and gradual introduction of new immunotherapies in major countries.

Middle East & Africa

Steady growth supported by improving cancer diagnosis capabilities, rising focus on rare disease management, and gradual integration of modern treatment modalities in urban hospitals.

Key Segments:

➥ By Type
Epithelial mesothelioma dominates due to its higher prevalence and relatively better treatment response compared to other types. Sarcomatous mesothelioma is more aggressive and less responsive to therapy. Mixed (Biphasic) mesothelioma includes both epithelial and sarcomatous cells, leading to varied treatment outcomes.

➥ By Treatment Type

Chemotherapy:

Cisplatin and Pemetrexed remain the standard first-line chemotherapy options, offering improved survival when used together. Other chemotherapy combinations continue to be used for advanced or recurrent cases.

Immunotherapy:

Pembrolizumab, Nivolumab, and Ipilimumab are key immunotherapy drugs showing strong efficacy in improving survival, especially in unresectable and advanced-stage mesothelioma.

Targeted Therapy:

Targeted therapy focuses on specific molecular markers, offering personalized treatment with fewer side effects, though currently limited by biomarker availability.

Radiation Therapy:

Used to relieve symptoms and reduce tumor spread, often combined with surgery or chemotherapy for improved local control.

Tri-Modality Therapy:

A combined approach involving surgery, chemotherapy, and radiation therapy, providing the most aggressive and comprehensive treatment for eligible patients.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/malignant-pleural-mesothelioma-treatment-market?sai-v

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.